Stryker announces definitive agreement to acquire Vertos Medical, Inc., expanding interventional pain management solutions
Stryker (NYSE: SYK) has announced a definitive agreement to acquire Vertos Medical Inc., a private company specializing in minimally invasive treatments for chronic lower back pain caused by lumbar spinal stenosis. This acquisition aims to expand Stryker's interventional pain management solutions, particularly in ambulatory surgery centers.
Vertos Medical's mild® procedure offers pain relief and improved mobility without major surgery, addressing a condition affecting millions globally. Andy Pierce, Group President at Stryker, emphasized the company's commitment to restoring patients' quality of life through interventional solutions. The transaction, subject to customary closing conditions, is expected to strengthen Stryker's portfolio in the growing field of minimally invasive pain management.
Stryker (NYSE: SYK) ha annunciato un accordo definitivo per acquisire Vertos Medical Inc., un'azienda privata specializzata in trattamenti minimamente invasivi per il dolore cronico alla schiena causato da stenosi spinale lombare. Questa acquisizione mira a espandere le soluzioni per la gestione del dolore interventistico di Stryker, in particolare nei centri di chirurgia ambulatoriale.
La procedura mild® di Vertos Medical offre sollievo dal dolore e una mobilità migliorata senza la necessità di un intervento chirurgico maggiore, affrontando una condizione che colpisce milioni di persone in tutto il mondo. Andy Pierce, Presidente di Gruppo presso Stryker, ha sottolineato l'impegno dell'azienda a ripristinare la qualità della vita dei pazienti attraverso soluzioni interventistiche. La transazione, soggetta a condizioni di chiusura consuete, si prevede rafforzi il portafoglio di Stryker nel crescente campo della gestione del dolore minimamente invasivo.
Stryker (NYSE: SYK) ha anunciado un acuerdo definitivo para adquirir Vertos Medical Inc., una empresa privada especializada en tratamientos mínimamente invasivos para el dolor crónico de espalda causado por estenosis espinal lumbar. Esta adquisición tiene como objetivo ampliar las soluciones de manejo del dolor interventivo de Stryker, particularmente en centros de cirugía ambulatoria.
El procedimiento mild® de Vertos Medical ofrece alivio del dolor y una mejora en la movilidad sin cirugía mayor, abordando una condición que afecta a millones de personas en todo el mundo. Andy Pierce, Presidente de Grupo en Stryker, enfatizó el compromiso de la empresa de restaurar la calidad de vida de los pacientes a través de soluciones interventivas. La transacción, sujeta a condiciones de cierre habituales, se espera que fortalezca el portafolio de Stryker en el creciente campo del manejo del dolor mínimamente invasivo.
Stryker (NYSE: SYK)는 만성 요통 치료를 전문으로 하는 사기업 Vertos Medical Inc.를 인수하기 위한 확정 계약을 발표했습니다. 이번 인수는 특히 외래 수술 센터에서의 Stryker의 중재적 통증 관리 솔루션을 확장하는 것을 목표로 합니다.
Vertos Medical의 mild® 절차는 대수술 없이 통증을 완화하고 이동성을 향상시키며, 수백만 명의 전 세계에서 영향을 받는 질환을 다룹니다. Stryker의 그룹 프레젠트인 Andy Pierce는 중재적 솔루션을 통해 환자의 삶의 질을 회복하려는 회사의 의지를 강조했습니다. 이번 거래는 관례적인 종결 조건에 따라 진행되며, Stryker의 최소한의 침습적 통증 관리 분야에서의 포트폴리오를 강화할 것으로 예상됩니다.
Stryker (NYSE: SYK) a annoncé un accord définitif pour acquérir Vertos Medical Inc., une entreprise privée spécialisée dans les traitements peu invasifs pour le dos chronique douleur causée par la sténose spinale lombaire. Cette acquisition vise à étendre les solutions de gestion de la douleur interventionnelle de Stryker, en particulier dans les centres de chirurgie ambulatoire.
La procédure mild® de Vertos Medical offre un soulagement de la douleur et une mobilité améliorée sans chirurgie majeure, traitant un état qui affecte des millions de personnes dans le monde. Andy Pierce, président du groupe chez Stryker, a souligné l'engagement de l'entreprise à restaurer la qualité de vie des patients grâce à des solutions interventionnelles. La transaction, soumise à des conditions de clôture habituelles, devrait renforcer le portefeuille de Stryker dans le domaine en pleine croissance de la gestion de la douleur peu invasive.
Stryker (NYSE: SYK) hat einen definitiven Vertrag zur Übernahme von Vertos Medical Inc. angekündigt, einem privaten Unternehmen, das sich auf minimalinvasive Behandlungen bei chronischen Rückenschmerzen aufgrund von lumbaler Spinalstenose spezialisiert hat. Diese Übernahme zielt darauf ab, Strykers interventionsbasierte Schmerzmanagementlösungen zu erweitern, insbesondere in ambulanten Operationszentren.
Das mild®-Verfahren von Vertos Medical bietet Schmerzlinderung und verbesserte Mobilität ohne größere Operationen und spricht damit ein Leiden an, das Millionen von Menschen weltweit betrifft. Andy Pierce, Gruppenpräsident von Stryker, betonte das Engagement des Unternehmens, die Lebensqualität der Patienten durch interventionsbasierte Lösungen wiederherzustellen. Die Transaktion, die üblichen Abschlussbedingungen unterliegt, wird voraussichtlich das Portfolio von Stryker im wachsenden Bereich des minimalinvasiven Schmerzmanagements stärken.
- Expansion into the growing market of minimally invasive pain management solutions
- Acquisition of Vertos Medical's mild® procedure, offering pain relief without major surgery
- Potential for increased market reach in ambulatory surgery centers
- Strengthening of Stryker's interventional pain management portfolio
- None.
Stryker's acquisition of Vertos Medical is a strategic move to expand its presence in the lucrative interventional pain management market. With an aging population and increasing demand for minimally invasive procedures, this acquisition positions Stryker to capture a larger share of the spinal stenosis treatment market, estimated to reach
Stryker's acquisition of Vertos Medical represents a significant advancement in minimally invasive spine care. The mild® procedure addresses a critical need in treating lumbar spinal stenosis, which affects over 2.4 million Americans. Clinical studies have shown that the mild® procedure can provide
This acquisition strengthens Stryker's position in the rapidly growing ambulatory surgery center (ASC) market, projected to reach
Portage, Michigan, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis.
Lumbar spinal stenosis affects millions of people globally and is a leading cause of pain and disability. Patients today are seeking minimally invasive treatment options, valuing reduced recovery times and quicker returns to daily life. Vertos Medical’s mild® procedure provides a solution for pain relief and may improve mobility1,2 without the need for major surgery.
“We are committed to helping customers restore patients’ quality of life with interventional solutions to address chronic pain,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker.
“This acquisition strengthens our minimally invasive pain management portfolio with differentiated treatments and expands our reach across ambulatory surgery centers.”
“Allowing patients to get back to what matters most to them is what matters most to us,” said Eric Wichems, Vertos Medical’s Chief Executive Officer. “Stryker’s mission and focus on interventional solutions provides an opportunity to further improve patients' quality of life.”
This transaction is subject to customary closing conditions. Stryker and Vertos Medical Inc. will continue to operate as separate entities and proceed with business as usual until the transaction closes.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Sr. Director, Strategic Communications
beth.sizemore@stryker.com
References
- Deer TR, Chafin TB, Costandi SJ, Qu H, Kim C, Jassal N, Patel K, Calodney A. The MOTION study: Two-year results of a real-world randomized controlled trial of the mild® procedure for treatment of lumbar spinal stenosis. Pain Pract. 2024 Jan;24(1):109-119.Deer TR, Costandi SJ, Washabaugh E, Chafin TB, Wahezi SE, Jassal N, Sayed D. The MOTION Study: A Randomized Controlled Trial with Objective Real-World Outcomes for Lumbar Spinal Stenosis Patients Treated with the mild® Procedure: One-Year Results. Pain Med. 2022 Apr 8;23(4):625-634.
FAQ
What company is Stryker (SYK) acquiring?
How will the Vertos Medical acquisition benefit Stryker (SYK)?
What is the main product of Vertos Medical that Stryker (SYK) is acquiring?
When was the acquisition of Vertos Medical by Stryker (SYK) announced?
